RxDoctor Payments Data

Minhazur Rahman, MD

Cardiovascular Disease · Slidell, LANPI 1003267451

Payments from drug & device makers

$6,421in general payments, 2019–2025

Across 136 payments — averaging $47.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abiomed$609
  • Amgen$584
  • Abbott$384
  • Shockwave Medical, Inc$364
  • AstraZeneca$297
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$1,44523%
  • Food & beverage$4,77874%
  • Education$1983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,421 in reported general payments places this provider in the 60th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,676
Medicare patients
363
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$67,763
EntrestoSacubitril/Valsartan48$55,418
JardianceEmpagliflozin41$47,219
BrilintaTicagrelor11$9,286
Praluent PenAlirocumab11$5,272
Metoprolol Succinate104$1,178
Atorvastatin Calcium92$824
Ranolazine ErRanolazine14$760
Amiodarone Hcl48$654
Ezetimibe34$654
ClopidogrelClopidogrel Bisulfate75$589
Rosuvastatin Calcium50$423
Amlodipine Besylate73$306
Losartan Potassium29$263
Spironolactone29$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$67,76363 claims
NovartisEntresto$191$55,41848 claims
Boehringer IngelheimJardiance$113$47,21941 claims
AstraZenecaBrilinta$297$9,28611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →